论文部分内容阅读
目的探讨托特罗定治疗留置尿管后导致膀胱不适的疗效。方法观察2005年10月至2010年8月由于各种原因留置尿管的患者,对比托特罗定治疗和安慰剂治疗的疗效,采用随机分组选择患者为治疗组或安慰剂组,治疗组口服托特罗定,每次2 mg,每天2次至拔管。结果尿道手术组完成的63例中,治疗组36例发生膀胱不适1例,安慰剂组27例发生膀胱不适7例;前列腺电切组完成的271例中,治疗组164例发生膀胱不适7例,安慰剂组107例发生膀胱不适43例;膀胱肿瘤电切组完成的76例中,治疗组34例均未发生膀胱不适,安慰剂组42例发生膀胱不适9例;输尿管镜组完成的363例中,治疗组217例发生膀胱不适9例,安慰剂组146例发生膀胱不适41例;经皮肾镜组167例中,治疗组72例发生膀胱不适2例,安慰剂组95例发生膀胱不适25例;腔内未操作组完成的88例中,治疗组47例发生膀胱不适4例,安慰剂组41例发生膀胱不适10例。结论托特罗定能够有效控制各种原因留置尿管后引起的膀胱不适症状。
Objective To investigate the efficacy of tolterodine in treating bladder discomfort after indwelling catheterization. Methods From October 2005 to August 2010, patients undergoing catheterization for various reasons were enrolled in this study. The efficacy of tolterodine and placebo was compared. Patients were randomized to receive either placebo or placebo. Patients in the treatment group received oral Tolterodine, 2 mg each time, twice daily to extubation. Results Of the 63 cases completed in the urethral operation group, 36 cases in the treatment group had bladder discomfort in 1 case, 27 cases in the placebo group had bladder discomfort in 7 cases, and 271 cases in the prostate resection group and 164 cases in the treatment group had bladder discomfort in 7 cases , 43 cases of bladder discomfort in 107 placebo patients, bladder discomfort in 34 patients in the treatment group, 9 cases of bladder discomfort in 42 patients in the placebo group, and 363 patients in the ureteroscopy group In the treatment group, 217 cases developed bladder discomfort in 9 cases, 146 cases in placebo group had bladder discomfort in 41 cases. Among the 167 cases in percutaneous nephrolithotomy group, 72 cases developed bladder discomfort in treatment group (2 cases) and 95 cases in placebo group Discomfort in 25 cases; cavity operation group completed 88 cases, the treatment group 47 cases of bladder discomfort in 4 cases, placebo group of 41 cases of bladder discomfort in 10 cases. Conclusion Tolterodine can effectively control bladder discomfort caused by indwelling catheter after various reasons.